We believe that evaluation of the two proprietary drugs, which exert pleiotropic CSC-targeted activities against primary patient-derived, spontaneously immortalized, low passage, highly tumorigenic and clonogenic prostate cancer cells with CD133+/high/CD44 +/high/CD49f+/ high/EpCAM+/ high phenotype is clinically relevant and has high potential as a novel anti-cancer drug combination. This evidence concerns the gene CD44 and Familial prostate cancer.